AR062375A1 - Cristal de epotilona b y composiciones farmaceuticas - Google Patents
Cristal de epotilona b y composiciones farmaceuticasInfo
- Publication number
- AR062375A1 AR062375A1 ARP070103603A ARP070103603A AR062375A1 AR 062375 A1 AR062375 A1 AR 062375A1 AR P070103603 A ARP070103603 A AR P070103603A AR P070103603 A ARP070103603 A AR P070103603A AR 062375 A1 AR062375 A1 AR 062375A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- crystal
- epotilone
- epothilone
- ray diffraction
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 abstract 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06119043 | 2006-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062375A1 true AR062375A1 (es) | 2008-11-05 |
Family
ID=37685905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103603A AR062375A1 (es) | 2006-08-16 | 2007-08-14 | Cristal de epotilona b y composiciones farmaceuticas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8178566B2 (enExample) |
| EP (1) | EP2064216A2 (enExample) |
| JP (1) | JP2010500387A (enExample) |
| KR (1) | KR20090038902A (enExample) |
| CN (1) | CN101506217B (enExample) |
| AR (1) | AR062375A1 (enExample) |
| AU (1) | AU2007286454A1 (enExample) |
| BR (1) | BRPI0715963A2 (enExample) |
| CA (1) | CA2658475A1 (enExample) |
| CL (1) | CL2007002362A1 (enExample) |
| IL (1) | IL196558A0 (enExample) |
| MA (1) | MA30656B1 (enExample) |
| MX (1) | MX2009001635A (enExample) |
| MY (1) | MY148355A (enExample) |
| NO (1) | NO20091081L (enExample) |
| NZ (1) | NZ574194A (enExample) |
| PE (1) | PE20081317A1 (enExample) |
| RU (1) | RU2009109352A (enExample) |
| TN (1) | TN2009000044A1 (enExample) |
| TW (1) | TW200815455A (enExample) |
| WO (1) | WO2008019820A2 (enExample) |
| ZA (1) | ZA200900227B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2927832C (en) | 2010-05-18 | 2021-03-23 | Cerulean Pharma Inc. | Cyclodextrin-containing polymer-therapeutic agent conjugates and their use |
| CN103910742B (zh) * | 2013-01-07 | 2016-07-13 | 浙江海正药业股份有限公司 | 一种制备埃博霉素b无定形粉末的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080016756A (ko) | 1998-02-05 | 2008-02-21 | 노파르티스 아게 | 유기화합물 함유 조성물 |
| US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| GB0029895D0 (en) | 2000-12-07 | 2001-01-24 | Novartis Ag | Organic compounds |
| HRP20050278A2 (en) * | 2002-09-23 | 2005-10-31 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
-
2007
- 2007-08-14 CN CN2007800304132A patent/CN101506217B/zh not_active Expired - Fee Related
- 2007-08-14 NZ NZ574194A patent/NZ574194A/en not_active IP Right Cessation
- 2007-08-14 AU AU2007286454A patent/AU2007286454A1/en not_active Abandoned
- 2007-08-14 KR KR1020097002958A patent/KR20090038902A/ko not_active Ceased
- 2007-08-14 AR ARP070103603A patent/AR062375A1/es not_active Application Discontinuation
- 2007-08-14 MX MX2009001635A patent/MX2009001635A/es not_active Application Discontinuation
- 2007-08-14 CA CA002658475A patent/CA2658475A1/en not_active Abandoned
- 2007-08-14 PE PE2007001090A patent/PE20081317A1/es not_active Application Discontinuation
- 2007-08-14 BR BRPI0715963-3A patent/BRPI0715963A2/pt not_active IP Right Cessation
- 2007-08-14 JP JP2009524113A patent/JP2010500387A/ja active Pending
- 2007-08-14 CL CL200702362A patent/CL2007002362A1/es unknown
- 2007-08-14 US US12/376,973 patent/US8178566B2/en not_active Expired - Fee Related
- 2007-08-14 WO PCT/EP2007/007173 patent/WO2008019820A2/en not_active Ceased
- 2007-08-14 RU RU2009109352/04A patent/RU2009109352A/ru not_active Application Discontinuation
- 2007-08-14 MY MYPI20090415A patent/MY148355A/en unknown
- 2007-08-14 EP EP07801648A patent/EP2064216A2/en not_active Withdrawn
- 2007-08-15 TW TW096130206A patent/TW200815455A/zh unknown
-
2009
- 2009-01-12 ZA ZA2009/00227A patent/ZA200900227B/en unknown
- 2009-01-15 IL IL196558A patent/IL196558A0/en unknown
- 2009-02-13 TN TN2009000044A patent/TN2009000044A1/fr unknown
- 2009-02-20 MA MA31654A patent/MA30656B1/fr unknown
- 2009-03-11 NO NO20091081A patent/NO20091081L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090038902A (ko) | 2009-04-21 |
| TW200815455A (en) | 2008-04-01 |
| CL2007002362A1 (es) | 2008-08-08 |
| WO2008019820A3 (en) | 2008-04-17 |
| JP2010500387A (ja) | 2010-01-07 |
| US8178566B2 (en) | 2012-05-15 |
| NZ574194A (en) | 2011-12-22 |
| CN101506217B (zh) | 2012-09-05 |
| CN101506217A (zh) | 2009-08-12 |
| MY148355A (en) | 2013-03-29 |
| MX2009001635A (es) | 2009-02-23 |
| TN2009000044A1 (en) | 2010-08-19 |
| IL196558A0 (en) | 2009-11-18 |
| NO20091081L (no) | 2009-03-16 |
| ZA200900227B (en) | 2009-12-30 |
| WO2008019820A2 (en) | 2008-02-21 |
| MA30656B1 (fr) | 2009-08-03 |
| AU2007286454A1 (en) | 2008-02-21 |
| US20100160393A1 (en) | 2010-06-24 |
| RU2009109352A (ru) | 2010-09-27 |
| PE20081317A1 (es) | 2008-10-28 |
| BRPI0715963A2 (pt) | 2013-08-06 |
| CA2658475A1 (en) | 2008-02-21 |
| EP2064216A2 (en) | 2009-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088221A (es) | Agonistas adrenoreceptores alfa2c | |
| PA8809601A1 (es) | Combinación anti-retroviral | |
| CL2008002539A1 (es) | Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral | |
| CL2008002538A1 (es) | Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral | |
| CL2007001994A1 (es) | Compuestos derivados de heterociclos nitrogenados que comprenden fosfonato y fosfinato, activadores de la glucocinasa; composicion farmaceutica que los comprende; y uso de los compuestos en el tratamiento de la diabetes, hiperglicemia, hiperinsulinemia, cancer, demencia, obesidad, entre otras. | |
| UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
| HN2012001162A (es) | Triazolopiridinas | |
| CL2008001017A1 (es) | Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad. | |
| CL2007001992A1 (es) | Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege | |
| UY32252A (es) | Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral | |
| MX2009003382A (es) | Derivados de sulfonamidas sustituidos. | |
| CL2009000023A1 (es) | Compuestos derivados de heterociclos de nitrogeno y azufre, moduladores de beta-amiloide; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer, angiopatia amiloide cerebral, hemorragia cerebral, demencia multiinfarto, demencia pugilistica o sindrome de down. | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| CL2008002049A1 (es) | Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| HN2008001393A (es) | Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| DOP2009000165A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| CR9723A (es) | Nueva forma cristalina de un derivado de piridazino[4,5-b] indol | |
| CU20120002A7 (es) | DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA | |
| DOP2012000312A (es) | Triazolopiridinas sustituidas | |
| AR109263A2 (es) | Composición que comprende moxidectina | |
| GT200600200A (es) | Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato | |
| CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
| ECSP066883A (es) | Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes | |
| CR9391A (es) | Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR111471A2 (es) | Composición de combinación sinérgica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |